Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Inari Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Inari Medical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.41
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

May 23

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

May 02

Inari Medical: Buy On Growing TAM

Mar 27

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Mar 08

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jul 25

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Jun 18

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues

Apr 17

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Dec 07

Study assessing Inari Medical's blood clot removal system shows low rate of adverse events

Sep 19

Inari Medical: Growth Set To Reaccelerate In The Back Half Of The Year

Sep 07

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von NARI in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von NARI gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Inari Medical Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von NARI im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (NARI)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (NARI)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von NARI im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von NARI im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von NARI, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da NARI keine Ausschüttungen gemeldet hat.

Inari Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Director notifies of intention to sell stock

Now 22% overvalued

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

Chief Financial Officer exercised options and sold US$273k worth of stock

Grant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc., William Hoffman, Andrew Hykes, and Mitch C. Hill on Behalf of Institutional Investor

Consensus EPS estimates fall by 73%, revenue upgraded

Inari Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 7.4% to US$66.00

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Inari Medical, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Chief Financial Officer exercised options and sold US$243k worth of stock

Inari Medical, Inc. Appoints Tim Benner as Senior Vice President of U.S. Sales

Inari Medical: Buy On Growing TAM

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc., Annual General Meeting, Apr 24, 2024

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Consensus EPS estimates fall by 325%

Price target decreased by 7.5% to US$76.50

Full year 2023 earnings: EPS misses analyst expectations

Inari Medical, Inc. Provides Revenue Guidance for the Full Year 2024

Inari Medical, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Consensus EPS estimates fall by 16%

Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024

Chief Financial Officer exercised options and sold US$405k worth of stock

Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)?

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

CEO, President & Director recently sold US$2.2m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) completed the acquisition of LimFlow SA.

CEO, President & Director notifies of intention to sell stock

Independent Chair of the Board recently bought US$3.0m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) agreed to acquire LimFlow SA for $415 million.

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI)

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business

Chief Financial Officer exercised options and sold US$438k worth of stock

CEO, President & Director recently sold US$2.4m worth of stock

CEO, President & Director notifies of intention to sell stock

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Inari Medical, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Chief Financial Officer exercised options and sold US$363k worth of stock

Inari Medical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. Announces Commercial Launch of Revcore and Triever16 Curve, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism

Inari Medical, Inc Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

Director recently sold US$5.7m worth of stock

Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 58%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues

Chief Financial Officer exercised options and sold US$415k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Chief Medical Officer exercised options and sold US$563k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 78%, revenue upgraded

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$425k worth of stock

Inari Medical, Inc. Announces First Patient Enrolled in the DEFIANCE Trial

Inari Medical, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2022 and for the Full Year 2023

CEO, President & Director exercised options and sold US$98k worth of stock

Chief Medical Officer exercised options and sold US$628k worth of stock

Chief Financial Officer exercised options and sold US$449k worth of stock

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Chief Financial Officer exercised options and sold US$511k worth of stock